Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Vemurafenib Plus Rituximab in Hairy Cell Leukemia
NCT05388123Phase 2Completed
- Sponsor
- Scripps Health
- Start
- Mar 2022
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib in hairy cell leukemia (HCL), sponsored by Scripps Health. Started Mar 2022; status: completed.
02
Drugs
vemurafenib
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT05388123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05388123.